INM · Inmed Pharmaceuticals Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $4.94M | $4.60M | $4.14M | $1.90M | - |
| Cost of Revenue | $3.24M | $3.50M | $2.42M | $545.9K | - |
| Gross Profit | $1.71M | $1.10M | $1.40M | $543.5K | - |
| R&D | $2.85M | $3.77M | $3.73M | $7.28M | $5.81M |
| SG&A | $6.56M | $5.25M | $5.85M | $6.87M | $3.23M |
| Total Operating Expenses | $9.65M | $9.30M | $9.78M | $17.81M | $9.15M |
| D&A | $212.8K | $219.6K | $202.2K | $185.7K | $112.4K |
| Operating Income | ($8.16M) | ($7.67M) | ($7.95M) | ($10.20M) | - |
| Interest Expense | - | - | - | - | - |
| Income Tax | - | $7.1K | $13.1K | - | - |
| Net Income | ($8.16M) | ($7.68M) | ($7.95M) | ($18.60M) | ($8.94M) |
| EPS - Basic | ($8.36) | ($20.20) | ($65.00) | ($759.20) | - |
| EPS - Diluted | ($8.36) | ($20.20) | ($65.00) | ($759.20) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $11.08M | $6.57M | $8.91M | $6.18M | $7.36M |
| Accounts Receivable | $465.1K | $352.8K | $260.4K | $88.0K | $11.9K |
| Inventory | $961.2K | $1.24M | $1.62M | $2.49M | - |
| Accounts Payable | $370.1K | $41.0K | $544.2K | - | - |
| Current Assets | $12.87M | $8.69M | $11.33M | $9.60M | $8.38M |
| Total Assets | $15.58M | $11.82M | $14.11M | $12.79M | $9.78M |
| Current Liabilities | $1.84M | $1.97M | $2.00M | $3.32M | $2.22M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $2.15M | $2.62M | $2.02M | $3.71M | $2.40M |
| Stockholders' Equity | $13.43M | $9.21M | $12.09M | $9.08M | $7.38M |
| Retained Earnings | ($117.24M) | ($109.08M) | ($101.40M) | ($93.45M) | ($74.85M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($7.77M) | ($6.99M) | ($7.28M) | ($15.58M) | ($7.37M) |
| Investing Cash Flow | - | ($9.3K) | ($661.8K) | ($673.0K) | $3.79M |
| Financing Cash Flow | $12.27M | $4.65M | $10.68M | $15.07M | ($31.0K) |
| CapEx | - | $9.3K | $160.0K | $39.1K | $42.6K |
| Free Cash Flow | - | ($7.00M) | ($7.44M) | ($15.62M) | ($7.42M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 34.5% | 23.9% | 33.9% | 28.5% | - |
| Operating margin | -165.1% | -166.8% | -192.2% | -535.9% | - |
| EBITDA margin | -160.8% | -162.0% | -187.3% | -526.1% | - |
| Net margin | -165.1% | -166.9% | -192.2% | -976.9% | - |
| Free cash flow margin | - | -152.1% | -180.0% | -820.5% | - |
| FCF / Net income | - | 0.91 | 0.94 | 0.84 | 0.83 |
| R&D / Revenue | 57.7% | 81.9% | 90.2% | 382.5% | - |
| SG&A / Revenue | 132.7% | 114.2% | 141.4% | 360.7% | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -52.4% | -64.9% | -56.3% | -145.5% | -91.4% |
| Return on equity | -60.8% | -83.4% | -65.7% | -204.9% | -121.2% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 6.99 | 4.41 | 5.66 | 2.89 | 3.78 |
| Quick ratio | 6.47 | 3.78 | 4.86 | 2.14 | 3.78 |
| Cash ratio | 6.02 | 3.33 | 4.45 | 1.86 | 3.32 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | 1.16 | 1.28 | 1.17 | 1.41 | 1.33 |
| Liabilities / Assets | 0.14 | 0.22 | 0.14 | 0.29 | 0.25 |
| Efficiency | |||||
| Asset turnover | 0.32 | 0.39 | 0.29 | 0.15 | - |
| Inventory turnover | 3.37 | 2.81 | 1.50 | 0.22 | - |
| Days sales outstanding | 34d | 28d | 23d | 17d | - |
| Days inventory outstanding | 108d | 130d | 243d | 1665d | - |
| Days payable outstanding | 42d | 4d | 82d | - | - |
| Cash conversion cycle | 101d | 154d | 184d | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 0.2x | 4.4x | 3.8x | 14.5x | 1125.3x |
| P / S | 0.6x | 8.8x | 11.0x | 69.2x | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | 7.5% | 11.2% | 117.2% | - | - |
| Revenue CAGR (3y) | 37.4% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | 55.0% | -21.5% | 158.1% | - | - |
| Operating income growth (YoY) | -6.4% | 3.5% | 22.1% | - | - |
| Net income growth (YoY) | -6.3% | 3.4% | 57.3% | -108.1% | - |
| EPS growth (YoY) | 58.6% | 68.9% | 91.4% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | - | 6.0% | 52.4% | -110.6% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 45.9% | -23.9% | 33.2% | 23.1% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-06-30.
Business segments
$4.60M totalBay Medica Commercial$4.60M · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-4.55
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing InMed Pharmaceuticals Inc. against the 5 most active filers in the same SIC group.